AVITA Medical (ASX: AVH) secured a new contract manufacturing agreement and amended its existing distribution agreement for its biosynthetic wound matrix product PermeaDerm, for the treatment of wounds, with Stedical Scientific, according to a Tuesday filing with the Australian bourse.
Under the manufacturing agreement, effective Monday, the company will produce PermeaDerm at its Ventura, California facility, while the amended distribution deal revises revenue-sharing terms with Stedical, the filing said.
AVITA will retain 60% of sales, with Stedical receiving 40% after manufacturing costs. The agreement also sets performance milestones and extends the contract term, the filing added.
Shares of the company rose 7% in recent Tuesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.